Description
There are two distinct activities on offer to enhance knowledge and implementation of anti-inflammatory reliever (AIR) therapy:
- Maintenance of Certification Part IV Program
- CME Enduring Content
Content for these activities was developed by Michigan Medicine. More information on both activities can be found below.
Disclosure of Commercial Support
These activities were supported by an educational grant from AstraZeneca
Target Audience
These activities are designed to meet the educational needs of primary care and specialty providers involved in the chronic or acute management of persons with adult asthma.
Contact Information
For questions please contact: [email protected]
MOC PART IV Program
Release Date:
Enrollment begins November 1, 2025
Valid Through:
Enrollment closes February 28, 2026
Estimated Time to Complete Activity:
MOC Part IV – approximately 80-100 hours over 10 months
Credit Available
Participants in this activity are eligible for Part IV Maintenance of Certification (MOC) credit for most member Boards of the American Board of Medical Specialties (ABMS), including:
- American Board of Emergency Medicine – ONE PI Activity
- American Board of Family Medicine – ONE Improvement in Medical Practice Module
- American Board of Internal Medicine – 30 Practice Assessment Points
MOC IV Overview
This quality improvement program focuses on increasing the use of AIR therapy in clinical practice. It's a great opportunity to enhance patient outcomes, streamline treatment approaches, and receive MOC IV credit for making a meaningful impact in asthma management.
Program Objectives
To increase uptake of AIR Therapy via (choose one goal):
- Increase identification of at-risk patients by using evidence-based questionnaires.
- Reduction of SABA monotherapy in the high-risk asthma population (high risk is defined as: 2+OCS or ED/UC visit or hospitalization).
- Reduction of the proportion of patients receiving 3+ SABA canisters during the intervention period as compared to baseline.
- Reduce SABA overprescribing by implementing a process to reduce the number of SABA canisters provided.
Instructions for Participation and Credit
- Visit the MOC Part IV Program website www.airmoc.org to enroll in the program
- Credit for program completion will be provided commensurate with ABMS guidelines: https://www.abms.org/wp-content/uploads/2024/05/abms-portfolio-program-credit-translation-chart-2024-06.pdf
- Certificates will be emailed to participants.
CME Enduring Content Offering
Release Date:
November 1, 2025
Valid Through:
October 31, 2028
Estimated Time to Complete Activity:
CME Enduring Content – 2 hours
Credit Available
The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Michigan Medical School designates this enduring content activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Enduring Material Overview
Provides learners with an understanding of inhaled corticosteroid-based fast-acting reliever strategies for the management of asthma.
This activity for primary care and specialty healthcare professionals is intended to provide a better understanding of the role of inhaled anti-inflammatory based reliever (AIR) therapies in the acute and chronic management of asthma. AIR therapy is now recommended by the GINA strategy and US NAEPP asthma guidelines to better manage inflammation associated with respiratory symptoms and to reduce exacerbations. This is a paradigm change for asthma management, necessitating education of clinicians and patients.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Understand the clinical science supporting prescribing an inhaled steroid with reliever bronchodilators
- Discuss current practices employing albuterol reliever inhalers in asthma management and opportunities for change
- Describe and utilize the current GINA and NAEPP recommendations for using AIR Therapy in asthma management
- Discuss patient cases employing AIR therapy in asthma
Instructions for Participation and Credit
There are no fees for participating in and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Participate in the online activity by clicking the “Start Activity” button at the top of the page
- Upon completion, claim credit and evaluate the content in the Michigan Medicine MiCME platform
Faculty
Njira Lugogo, MD
Njira Lugogo, MD, MS, Professor of Internal Medicine, is the Division of Pulmonary & Critical Care Medicine's Asthma Program Director. Dr. Lugogo completed her Medical Degree at the Medical College of Virginia, Richmond, VA. She completed her Internal Medicine Residency at Wake Forest University, Winston-Salem, NC. After she completed her Pulmonary & Critical Care Medicine Fellowship at Duke University, she rose to Assistant Professor. At Duke, Dr. Lugogo served as the Medical Director of the Duke Asthma Allergy and Airway Center and Director of the Asthma Clinical Trails Group and Pulmonary Clinical Research Unit. She joined the University of Michigan Pulmonary & Critical Care Medicine faculty in August, 2017.
Ann Arbor, MI
Disclosures of Conflict of Interest
All relevant financial relationships have been mitigated prior to the commencement of the CME activity.
Dr. Njira Lugogo (Planner and Faculty)
- Research: Clinical trials - Amgen, AstraZeneca, Avillion, Bellus, Evidera, Gossamer Bio, Genentech, GSK, Janssen, NIOX, Pfizer, Regeneron, Roche, Sanofi, Novartis, and Teva.
- Consultation/Advisory Board: AbbVie, Amgen, Apogee, AstraZeneca, Avillion, Foresee, Genentech, GSK, Incyte, NIOX, Novartis, Regeneron, Sanofi, and TEVA.
- Speaker fees for non speaker’s bureau scientific talks: AstraZeneca, GSK, Regeneron, Sanofi, and TEVA.
Dr. Neil Skolnik (Co-planner and Faculty)
- Advisor: AstraZeneca; Teva Pharmaceutical Industries; Lilly; Sanofi; Abbott; Novo Nordisk; GSK
- Speakers Bureau: AstraZeneca; Lilly; Teva Pharmaceutical Industries; GSK
- Grant or research support: AstraZeneca; Novo Nordisk; Novartis Corporation Pharmaceuticals
Dr. Reuben Strayer (Co-planner and Faculty)
- Dr. Reuben Strayer has nothing to disclose
Dr. Luis Nannini (Co-planner and Faculty)
- Honoraria: AstraZeneca
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.